ARGX vs. ELV: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ARGX and ELV, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
ELV’s market capitalization of 78.59 billion USD is significantly greater than ARGX’s 33.18 billion USD, highlighting its more substantial market valuation.
ELV carries a higher beta at 0.62, indicating it’s more sensitive to market moves, while ARGX (beta: 0.04) exhibits greater stability.
ARGX trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, ELV is a standard domestic listing.
| Symbol | ARGX | ELV |
|---|---|---|
| Company Name | argenx SE | Elevance Health Inc. |
| Country | NL | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical - Healthcare Plans |
| CEO | Timothy Van Hauwermeiren EMBA, | Gail Koziara Boudreaux |
| Price | 543.48 USD | 347.84 USD |
| Market Cap | 33.18 billion USD | 78.59 billion USD |
| Beta | 0.04 | 0.62 |
| Exchange | NASDAQ | NYSE |
| IPO Date | May 18, 2017 | October 30, 2001 |
| ADR | Yes | No |
Historical Performance
This chart compares the performance of ARGX and ELV by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ARGX
16.83%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
In the upper quartile for the Biotechnology industry, ARGX’s Return on Equity of 16.83% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
ELV
13.94%
Medical - Healthcare Plans Industry
- Max
- 13.94%
- Q3
- 13.62%
- Median
- 11.42%
- Q1
- 7.74%
- Min
- 6.98%
In the upper quartile for the Medical - Healthcare Plans industry, ELV’s Return on Equity of 13.94% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Return on Invested Capital
ARGX
-118.38%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
ARGX has a negative Return on Invested Capital of -118.38%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
ELV
7.60%
Medical - Healthcare Plans Industry
- Max
- 15.50%
- Q3
- 7.12%
- Median
- 5.48%
- Q1
- -3.47%
- Min
- -15.02%
In the upper quartile for the Medical - Healthcare Plans industry, ELV’s Return on Invested Capital of 7.60% signifies a highly effective use of its capital to generate profits when compared to its peers.
Net Profit Margin
ARGX
37.53%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
A Net Profit Margin of 37.53% places ARGX in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
ELV
3.23%
Medical - Healthcare Plans Industry
- Max
- 3.23%
- Q3
- 2.62%
- Median
- 1.70%
- Q1
- 1.27%
- Min
- 1.22%
A Net Profit Margin of 3.23% places ELV in the upper quartile for the Medical - Healthcare Plans industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin
ARGX
-1.24%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
ARGX has a negative Operating Profit Margin of -1.24%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
ELV
4.30%
Medical - Healthcare Plans Industry
- Max
- 4.30%
- Q3
- 3.77%
- Median
- 2.61%
- Q1
- 1.60%
- Min
- -1.64%
An Operating Profit Margin of 4.30% places ELV in the upper quartile for the Medical - Healthcare Plans industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | ARGX | ELV |
|---|---|---|
| Return on Equity (TTM) | 16.83% | 13.94% |
| Return on Assets (TTM) | 13.45% | 4.94% |
| Return on Invested Capital (TTM) | -118.38% | 7.60% |
| Net Profit Margin (TTM) | 37.53% | 3.23% |
| Operating Profit Margin (TTM) | -1.24% | 4.30% |
| Gross Profit Margin (TTM) | 46.33% | 62.59% |
Financial Strength
Current Ratio
ARGX
7.29
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
ARGX’s Current Ratio of 7.29 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
ELV
1.43
Medical - Healthcare Plans Industry
- Max
- 1.91
- Q3
- 1.63
- Median
- 1.43
- Q1
- 0.85
- Min
- 0.78
ELV’s Current Ratio of 1.43 aligns with the median group of the Medical - Healthcare Plans industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
ARGX
0.01
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
Falling into the lower quartile for the Biotechnology industry, ARGX’s Debt-to-Equity Ratio of 0.01 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
ELV
0.71
Medical - Healthcare Plans Industry
- Max
- 1.06
- Q3
- 0.86
- Median
- 0.75
- Q1
- 0.66
- Min
- 0.66
ELV’s Debt-to-Equity Ratio of 0.71 is typical for the Medical - Healthcare Plans industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio
ARGX
-20.85
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
ARGX has a negative Interest Coverage Ratio of -20.85. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
ELV
6.23
Medical - Healthcare Plans Industry
- Max
- 6.23
- Q3
- 6.23
- Median
- 5.19
- Q1
- 4.64
- Min
- 3.18
ELV’s Interest Coverage Ratio of 6.23 is positioned comfortably within the norm for the Medical - Healthcare Plans industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | ARGX | ELV |
|---|---|---|
| Current Ratio (TTM) | 7.29 | 1.43 |
| Quick Ratio (TTM) | 6.68 | 1.43 |
| Debt-to-Equity Ratio (TTM) | 0.01 | 0.71 |
| Debt-to-Asset Ratio (TTM) | 0.01 | 0.25 |
| Net Debt-to-EBITDA Ratio (TTM) | -189.75 | 2.23 |
| Interest Coverage Ratio (TTM) | -20.85 | 6.23 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ARGX and ELV. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ARGX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ARGX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
ELV
1.92%
Medical - Healthcare Plans Industry
- Max
- 3.88%
- Q3
- 1.78%
- Median
- 0.73%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 1.92%, ELV offers a more attractive income stream than most of its peers in the Medical - Healthcare Plans industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio
ARGX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ARGX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
ELV
25.60%
Medical - Healthcare Plans Industry
- Max
- 63.88%
- Q3
- 29.91%
- Median
- 12.57%
- Q1
- 0.00%
- Min
- 0.00%
ELV’s Dividend Payout Ratio of 25.60% is within the typical range for the Medical - Healthcare Plans industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | ARGX | ELV |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 1.92% |
| Dividend Payout Ratio (TTM) | 0.00% | 25.60% |
Valuation
Price-to-Earnings Ratio
ARGX
48.48
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
ARGX’s P/E Ratio of 48.48 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
ELV
13.31
Medical - Healthcare Plans Industry
- Max
- 18.17
- Q3
- 17.32
- Median
- 15.48
- Q1
- 13.55
- Min
- 12.84
In the lower quartile for the Medical - Healthcare Plans industry, ELV’s P/E Ratio of 13.31 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Forward P/E to Growth Ratio
ARGX
1.27
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
A Forward PEG Ratio of 1.27 places ARGX in the upper quartile for the Biotechnology industry. This suggests the stock is potentially expensive compared to its peers relative to its growth forecast, which may warrant caution.
ELV
0.89
Medical - Healthcare Plans Industry
- Max
- 1.41
- Q3
- 1.09
- Median
- 0.85
- Q1
- 0.79
- Min
- 0.60
ELV’s Forward PEG Ratio of 0.89 is within the middle range of its peers in the Medical - Healthcare Plans industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
Price-to-Sales Ratio
ARGX
15.66
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
ARGX’s P/S Ratio of 15.66 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
ELV
0.43
Medical - Healthcare Plans Industry
- Max
- 0.94
- Q3
- 0.64
- Median
- 0.43
- Q1
- 0.27
- Min
- 0.16
ELV’s P/S Ratio of 0.43 aligns with the market consensus for the Medical - Healthcare Plans industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio
ARGX
7.35
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
ELV
1.85
Medical - Healthcare Plans Industry
- Max
- 4.08
- Q3
- 3.83
- Median
- 2.63
- Q1
- 1.74
- Min
- 0.96
ELV’s P/B Ratio of 1.85 is within the conventional range for the Medical - Healthcare Plans industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | ARGX | ELV |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 48.48 | 13.31 |
| Forward PEG Ratio (TTM) | 1.27 | 0.89 |
| Price-to-Sales Ratio (P/S, TTM) | 15.66 | 0.43 |
| Price-to-Book Ratio (P/B, TTM) | 7.35 | 1.85 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -432.72 | 21.39 |
| EV-to-EBITDA (TTM) | 4329.99 | 10.02 |
| EV-to-Sales (TTM) | 15.00 | 0.55 |